Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
146 results about "Thalidomide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
This medication is used to treat or prevent certain skin conditions related to Hansen's disease, once known as leprosy (erythema nodosum leprosum). Thalidomide is also used to treat a certain type of cancer (multiple myeloma).
Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor alpha (TNF-alpha) are used in the invention. Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and / or treatment of restenosis.
Owner:CELGENE CORP
Compositions and methods for the treatment of cancer
InactiveUS20020035090A1Improve toleranceReducing and avoiding adverse effectBiocideCarbohydrate active ingredientsCancer preventionSide effect
This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.
Owner:CELGENE CORP
Cytokine antagonists for the treatment of sensorineural hearing loss
InactiveUS6423321B2Improve hearingReduce developmentPeptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsIntravenous routeSensorineural hearing loss
Owner:TACT IP
Compositions and methods for the treatment of cancer
InactiveUS20020128228A1Reducing and avoiding adverse effectImprove toleranceBiocideAnimal repellantsIntestinal structureCancer prevention
This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Methods and compositions for inhibition of angiogenesis
InactiveUS7435745B2Inhibiting unwanted angiogenesisEasy to manageAntibacterial agentsBiocideDiseaseMetabolite
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
Owner:CELGENE CORP
Pharmaceutical compositions and dosage forms of thalidomide
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
Owner:CELGENE CORP
Improved formulations for drug-coated medical devices
The present invention is related to a medical device carrying at least on a portion of its surface at least one oxidation-insensitive drug or oxidation-insensitive polymer-free drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one antioxidant in relation to 100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected of taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the at least one lipophilic antioxidant is selected of nordihydroguaiarectic acid, resveratrol and propyl gallate, and wherein scoring or cutting balloons as medical devices are excluded.
Owner:INNORA
Methods for treating blood-born tumors with thalidomide
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Owner:CHILDRENS MEDICAL CENT CORP
Screening method utilizing thalidomide-targeting factor
ActiveUS20120192297A1Reduce teratogenic riskCompound screeningApoptosis detectionScreening methodEndocrinology
With an aim to provide means for developing a compound devoid of teratogenicity but retaining beneficial actions, a screening method for a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the bindability of the test substance with cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower bindability with cereblon or the fragment of cereblon than does thalidomide is provided.
Owner:TOKYO INST OF TECH +1
N2S2 chelate-targeting ligand conjugates
ActiveUS20050129619A1Sufficient amountHybrid immunoglobulinsRadioactive preparation carriersAngiostatinAbnormal tissue growth
The invention provides, in a general sense, a new labeling strategy employing compounds that are are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, a COX-2 inhibitor, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Compositions and methods for the treatment of colorectal cancer
This invention relates to compositions comprising thalidomide and irinotecan, which can be used in the treatment or prevention of colorectal cancer. The invention also relates to methods of treating or preventing colorectal cancer which comprise the administration of thalidomide and irinotecan to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of irinotecan which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS +1
Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
InactiveUS20050239719A1Lengthening time of remissionBiocideRespiratory disorderActive agentLung transplantation
Methods of treating, preventing and managing pulmonary hypertension are disclosed. Specific methods encompass the administration of thalidomide, or a pharmaceutically acceptable salt, solvate (e.g., hydrate), stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, surgery and / or lung transplantation. Specific second active agents are capable of reducing pulmonary artery pressure. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Anticancer sustained-release gel injection
InactiveCN101336890APharmaceutical delivery mechanismPharmaceutical non-active ingredientsLestaurtinibSolvent
The invention relates to an anticancer slow-release gel injection which contains slow-release microspheres containing an angiogenesis inhibitor, an amphiphilic block polymer, a solvent and a slow-release agent, wherein the composition of the amphiphilic block polymer and the non-organic solvent exhibit the property of temperature-sensitive gelation. After the in vivo injection, the injection turns into a stagnant and biodegradable water-insoluble gel and the gel slowly releases the drug contained therein for a plurality of weeks to a plurality of months. After the intratumoral or peritumoral injection, the anticancer slow-release gel injection can significantly reduce the general drug reactions and is used for treating tumors of different stages. The angiogenesis inhibitor is selected from SU5416, SU6668, bosutinib, sprycel, erlotinib, vandetanib, gefitnib, canertinib, lapatinib, lestaurtinib, masitinib, vatalanib, mubritinib, tandutinib, nilotinib, marimastat, nilotinib, pelitinib, telatinib, sunitinib, sorafenib, zarnestra, sirolimus, imatinfb, lenalidomide and thalidomide.
Owner:济南基福医药科技有限公司
Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
InactiveUS20070208057A1Preventing and prolonging their recurrenceLengthening time of remissionBiocideSenses disorderSide effectRadical radiotherapy
Methods of treating, preventing and / or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of thalidomide alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of thalidomide. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent
ActiveUS20080274120A1Reduced characteristicsReduced viabilityBiocidePeptide/protein ingredientsVincristineLeukemia
The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, Avastin®, an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
Owner:TOPOTARGET UK LTD
USE OF PHTHALIMIDE AND/OR SULPHONAMIDE DERIVATIVES IN THE TREATMENT OF DISEASES WHICH REQUIRE REDUCING THE TNF-alpha LEVELS AND AN EXOGENOUS SOURCE OF NITRIC OXIDE, PHTHALIMIDE DERIVATIVES, SULPHONAMIDE DERIVATIVES, AND A METHOD FOR OBTAINING A SULPHONAMIDE DERIVATIVE
InactiveUS20100324107A1Improve the quality of lifeBiocideOrganic chemistryPhthalocyanine derivativesNitric oxide
Owner:UNIV ESTADUAL DE CAMPINAS UNICAMP +2
Methods and compositions for inhibition of angiogenesis with EM-138
InactiveUS6977268B2Easy to manageInhibiting unwanted angiogenesisBiocideSenses disorderDiseaseMetabolite
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Owner:CHILDRENS MEDICAL CENT CORP
Method of synthesis of 4-amino-thalidomide enantiomers
ActiveUS7812169B2Easy to manageInhibiting abnormal mitosis and/or unwanted angiogenesisAntibacterial agentsOrganic active ingredientsDiseaseMedicine
Owner:FORBES MEDI TECH +1
Compositions and methods for the treatment of colorectal cancer
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS +1
Thalidomide and its derivatives preparation method
The method for synthesizing thalidomide and its derivative includes the following steps: adding phthalic anhydride and glutamine at 120-150 deg.C, addition quantity of phthalic anhydride is 1-5 times that of glutamine, heating, stirring, reacting for 20-40 min., then slowly heating to 160-220 deg.C, vacuum pumping, after 2-20 hr, stopping reaction, adding 1,4-dioxane, heating and stirring to make said material into solution, decompressing and evaporating out dioxane, adding acetone, stirring, filtering, washing with water and settling, washing with acetone and vacuum drying to obtain the invented thalidomide. Said invention utilizes 2-position or 4-position CH3, CH2CH3, OCH3, F, Cl, Br or NO2 substituted phthalic anhydride and glutamine, and makes them react together, so that the correspondent thalidomide derivative can be obtained.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
InactiveUS20050182097A1Extension of timeBiocideNervous disorderMedicineAmyotrophic lateral sclerosis
Methods of treating, preventing and / or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) and related syndromes are disclosed. Specific methods encompass the administration of thalidomide, or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
Owner:CELGENE CORP
Liposomes for treatment of multiple myeloma
A method for treating multiple myeloma in newly diagnosed or previously treated patients is described. The method comprises administering a composition consisting of a combination of chemotherapeutic agents of an anthracycline antibiothic, preferably entrapped in a liposome, dexamethasone, and thalidomide, and, optionally, a reduced dose of vincristine.
Owner:ALZA CORP
Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
ActiveUS20160015728A1Less toxicityIncreases effectiveness and therapeutic indexOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsNormal boneAnticarcinogen
The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.
Owner:RUTGERS THE STATE UNIV +1
Dual Small Molecule Inhibitors of Cancer and Angiogenesis
The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Anticancer composition containing Sirolimus
InactiveCN1973822AGrowth inhibitionInhibitionOrganic active ingredientsPeptide/protein ingredientsErlotinibMicrosphere
The anticancer composition containing sirolimus is one kind of slow releasing injection comprising slow released microsphere and special solvent containing suspending agent or slow releasing implant. The effective anticancer component is sirolimus, proteolytic enzyme selected from collagenase, hyaluornidase, etc and blood vessel inhibitor selected from gefitinib, thalidomide, etc. The slow releasing supplementary material is selected from polylactic acid, polyethylene glycol, polifeprosan, etc; the suspending agent is selected from sodium carboxymethyl cellulose, etc and has viscosity of 100cp-3000cp. The slow releasing injection and the slow releasing implant are used in treating tumor alone or in conjunction with chemotherapy.
Owner:SHANDONG LANJIN PHARMA +1
Analogue of thalidomide and preparation method
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
Use of Thalidomide for Alzheimers Disease Treatment and Prevention
Owner:SHEN YONG +1
New method of synthesizing thalidomide and its derivative
Owner:TIANJIN HEMAY BIO TECH CO LTD
Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
ActiveUS20170106003A1Organic active ingredientsPharmaceutical delivery mechanismGlucocorticoidCancer therapy
The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
Owner:ONCOTRACKER INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com